USPTO serial 85331949
Serial No. 85331949
Reviewed by CopyMark Law Group
Reg. 4133358Status 710
- Filing date
- Status date
- Registration date
- Apr 24, 2012
- Examiner
- JUN, WON KYUNG WENDY
- Law office
- TMEG LAW OFFICE 103
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with Serial No. 85331949?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer Sheehan Anderson
Jennifer Sheehan Anderson Bridge Intellectual Property Services PLLC143 CadyCenter, Suite 209Northville, MI 48167UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in chemotherapy, herbal supplements, pharmaceutical preparations for the treatment of the digestive system, respiratory system, immune system, circulatory system, nervous system, namely, antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals, bismuth preparations for pharmaceutical purposes, inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders, pharmaceutical antitussive-cold preparations, pharmaceutical anti-allergic preparations and substances, anticoagulants, antidepressants, appetite suppressants; pharmaceutical preparations for use in chemotherapy, for the treatment of gout, for the treatment of heart rhythm disorders, for the treatment of infectious diseases; a drug delivery agents in the form of polymer-based oral tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals acting on the central nervous system for the treatment of gastro-intestinal diseases, for the treatment of pulmonary hypertension, for ocular or intraocular surgery, for the treatment of hormonal disorders and the prevention of osteoporosis, for treating allergic rhinitis and asthma, for treating diabetes, for treating skin disorders, for use in dermatology, for treating wounds, for treating urological diseases, for treating dry skin caused by pregnancy, for treating chloasma, for hydrating the skin during pregnancy, for treating pregnancy blemishes, for preventing skin blemishes during pregnancy, and for preventing stretch marks and swelling in the legs; potassium preparations for pharmaceutical purposes; vitamin and mineral preparations for use as ingredients in the food and pharmaceutical industry; dietary supplement drink mixes; anti allergic medicines; medicines for the treatment of gastrointestinal diseases; Chinese patent medicines for the treatment of the digestive system, respiratory system, immune system, and nervous system, namely, antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; blood substitutes for human use; alcohol for topical use; cachou for pharmaceutical purposes; diagnostic reagents for medicinal use, baby food, medicated candy, antimicrobial coatings to prevent the growth of mold, mildew, bacteria and fungus on various surfaces; veterinary preparations, namely, anti-infective products; bacterial and bacteriological preparations, namely, bacteriostats, biochemical preparations, biological and chemical preparations, namely, hepatitis B vaccine for the prevention of hepatitis B virus infection; clinical medical reagents; diagnostic preparations for medical purposes; electrophoresis gels for medical purposes; ferments for medical use; nucleic acid sequences and reagents for medical purposes; plant extracts for medical purposes; reagents for medical use; pain relief medication for use in treatment of intestinal bacteria; veterinary vaccines, yeast or yeast extracts for medical or pharmaceutical purposes; insect repellents, sanitary napkins, traditional Chinese medicine packs comprised of antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; traditional Chinese medicines, namely, balms for medical purposes, medicinal oils, capsules sold empty for pharmaceuticals, medicinal teas, dietetic foods adapted for medical use; processed food adapted for medical purposes; menstrual symptom treatment preparations, vitamins, vitamin preparations, ginseng for medicinal use; medicinal herbal preparations; Proprietary Chinese medicines, namely, cardiovascular pharmaceuticals, cardiovascular treatment preparations, herbal pills for the treatment of diabetes, pharmaceutical preparations for treating diabetes, prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; dietetic beverages adapted for medical purposes; fungicides, herbicides; dietetic foods adapted for medical purposes, namely, swallow nests, deer tendons, deer penises, deer tails, deer antlers, slices of antler; dressings for wounds, burns, surgery; haemostatic pencils; fillings for teeth; medical adhesive tapes | SECTION 8 - CANCELLED | Sep 1, 2006 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 4, 2022 | CAEX | CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9 | — |
| Feb 10, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 10, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 10, 2022 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Feb 10, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 10, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 10, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 24, 2021 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Apr 24, 2018 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Apr 24, 2018 | 8.OK | REGISTERED - SEC. 8 (6-YR) ACCEPTED | The USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline. |
| Apr 24, 2018 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 18, 2018 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Apr 24, 2017 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Apr 24, 2012 | R.SR | REGISTERED-SUPPLEMENTAL REGISTER | Your mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application. |
| Mar 20, 2012 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 15, 2012 | CNTA | APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER | — |
| Mar 15, 2012 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 15, 2012 | ALIE | ASSIGNED TO LIE | — |
| Mar 15, 2012 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 15, 2012 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 15, 2012 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 23, 2012 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 22, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 22, 2012 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 16, 2011 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 16, 2011 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 16, 2011 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 14, 2011 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 3, 2011 | MDSC | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Jun 2, 2011 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 31, 2011 | NWAP | NEW APPLICATION ENTERED | — |